Four sessions across two days focusing on key drug discovery and development application areas oforgan-on-a-chip technologies Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, including Novo Nordisk, Bristol Myers Squibb, and Pharmaron CAMBRIDGE, England, October 05, 2026--(BUSINESS WIRE)--CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more confident decision-making, today announced the full scientific programme for the 2026 'From Insight to Decision' e-Symposium.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.